$AQST News
Last published 3d ago
- 3d agoAQSTAquestive Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireWARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful
- 1w agoAQSTAquestive Therapeutics to Present Data at the 2026 ACAAI Annual MeetingGlobeNewswireWARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful
- 1w agoAQSTQ3 2026 Aquestive Therapeutics, Inc. Earnings Conference Call - AQUESTIVE THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Q3 2026 Equestive Therapeutics, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will
- 1w agoAQSTAquestive Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoAQSTETONAquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAnaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if
- 2w agoAQSTAquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ETGlobeNewswireWARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful
- 4w agoAQSTAquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027GlobeNewswireFDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned
- 4w agoETONAQSTEton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmGlobeNewswireDifferentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient
- 1mo agoAQSTAquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmGlobeNewswireResubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline
- 2mo agoAQSTAquestive Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireWARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
- 3mo agoAQSTQ2 2026 Aquestive Therapeutics, Inc. Earnings Conference Call - AQUESTIVE THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the second quarter Acquistive Therapeutics Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation,
- 3mo agoAQSTQ2 2026 Aquestive Therapeutics, Inc. Earnings Conference Call - AQUESTIVE THERAPEUTICS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the second quarter Acquistive Therapeutics Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation,
- 3mo agoAQSTAquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireSuccessfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues pre-launch medical
- 3mo agoAQSTAquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual FilmGlobeNewswireHuman factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK
- 3mo agoAQSTAquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ETGlobeNewswireWARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
- 4mo agoAQSTAquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismGlobeNewswireWARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
- 6mo agoAQSTQ1 2026 Aquestive Therapeutics, Inc. Earnings Conference CallAQUESTIVE THERAPEUTICS INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the first quarter 2026 A Quest of Therapeutics earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, we'
- 6mo agoAQSTAquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireReaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the
- 6mo agoAQSTAquestive Therapeutics Completes $150 Million Debt Refinancing with OaktreeGlobeNewswireWARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'
- 6mo agoAQSTAquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ETGlobeNewswireWARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'
- 6mo agoAQSTThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 4, 2026 in Aquestive Therapeutics, Inc. Lawsuit - AQSTGlobeNewswireNEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ:AQST). Shareholders who purchased shares of AQST during the class
- 7mo agoAQSTAQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallStPR NewswireSueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through...
- 7mo agoAQSTAquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmGlobeNewswireReaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by early May 2026 WARREN,
- 7mo agoAQSTAQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallStPR NewswireSueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through...
- 8mo agoAQSTAQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallStPR NewswireOn January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs...
- 8mo agoAQSTAquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'
- 8mo agoAQSTAQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive TherapeuticsBusiness WireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you
- 8mo agoAQSTQ4 2025 Aquestive Therapeutics, Inc. Earnings Conference CallAQUESTIVE THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to Equestria Therapeutics' 4th Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a que
- 8mo agoAQSTAquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireReaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada
- 8mo agoAQSTAQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered
- 8mo agoAQSTAQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or...
- 8mo agoAQSTINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered
- 8mo agoAQSTAquestive Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireWARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to
- 8mo agoAQSTAquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ETGlobeNewswireWARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'
- 8mo agoAQSTAquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireWARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to
- 8mo agoAQSTAquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual MeetingGlobeNewswireAnaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive
- 8mo agoAQSTAQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered
- 8mo agoAQSTAquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical OfficerGlobeNewswireBoard-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026
- 9mo agoAQSTINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or...
- 9mo agoAQSTINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or...
- 9mo agoAQSTAquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™GlobeNewswireDeficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant
- 9mo agoAQSTAQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered
- 10mo agoAQSTBREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies Deficiencies; Investors Should Contact Block & Leviton To Potentially Recover LossesGlobeNewswireBOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aquestive Therapeutics, Inc. (NASDAQ:AQST) for potential securities law violations. Investors who have lost money in their Aquestive
- 10mo agoAQSTAquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business UpdateGlobeNewswireAnnounces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm NDA application is
- 11mo agoAQSTAquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireWARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to
- 1y agoAQSTAquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePlanned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened
- 1y agoAQSTTLSAAquestive Therapeutics Announces Leadership Expansion to Support GrowthGlobeNewswireChanges strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company's ongoing development initiatives Matthew Davis, M.D.,
- 1y agoAQSTAquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper SandlerGlobeNewswireWARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'
- 1y agoAQSTAquestive Therapeutics to Attend 2025 ACAAI Annual MeetingGlobeNewswireWARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'
- 1y agoAQSTAquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ETGlobeNewswireWARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients'